Alaunos Therapeutics, INC 10-Q quarterly reports

Alaunos Therapeutics reports Q1 2026 net loss of $1.0 million while highlighting preclinical progress for its obesity program, ALN1003.

Alaunos Therapeutics reports a net loss and limited cash runway into Q1 2026, with new existential risks from the ongoing U.S. government shutdown impacting its ability to raise capital and maintain Nasdaq compliance.

Alaunos Therapeutics secured $3.26 million in financing and pivoted to an obesity program, but faces Nasdaq delisting and going concern doubts.

Alaunos Therapeutics reports Q1 2025 results, highlighting strategic reprioritization, ongoing small molecule obesity program development, and substantial doubt about its ability to continue as a going concern.

Alaunos Therapeutics announced its Q3 2024 results, highlighting a strategic reprioritization, the wind-down of its TCR-T program, and the evaluation of a small molecule oral obesity treatment program.

Alaunos Therapeutics reported its Q2 2024 financial results while undergoing a strategic reprioritization and cost-reduction efforts.

Alaunos Therapeutics reports a net loss of $1.7 million for Q1 2024 as it continues to explore strategic alternatives after halting its clinical trial.